A Model for the Strategic Management of Innovation and R&D Based on Real Options Valuation: Assessing the Options to Abandon and Expand Clinical Trials in Pharmaceutical Firms
2001 ◽
Vol 46
(1)
◽
pp. 1-32
◽
Keyword(s):
Keyword(s):
Keyword(s):
2018 ◽
Vol 20
(6)
◽
pp. 1888-1900
◽
Keyword(s):